Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
To clarify the efficacy of antiobesity drugs, this article reviews all long-term (> or =36 weeks), placebo-controlled trials of obesity pharmacotherapy published since 1960. Since fears of anorexiant-induced heart valve damage preclude many physicians and patients from even considering antiobesity drugs, this area is also reviewed in-depth. Electronic database and manual bibliography search was used to identify all relevant publications. While existing studies are too few and heterogeneous to warrant meta-analysis, their review does provide evidence highly relevant to the safety and efficacy of available anorexiants. Weight loss attributable to obesity pharmacotherapy (ie, in excess of placebo) in trials lasting 36 to 52 weeks was 8.1% or 7.9 kg for those receiving phentermine resin, 5.0 % or 4.3 kg for those receiving sibutramine hydrochloride, 3.4% or 3.4 kg for those receiving orlistat, and -1.5% or -1.5 kg for those receiving diethylpropion hydrochloride. Physiologic, pathologic, and epidemiological studies strongly support that anorexiant-induced valvulopathy is attributable to specific serotonergic properties of the fenfluramines that are not present with available weight loss drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494 · cited 1×
“In addition to the well-known association of obesity with elevation of traditional cardiac risk factors (blood pressure, cholesterol level), obesity also contributes to emerging cardiac risk factors including endothelial dysfunction,(16) hyperinsulinemia, and elevated C-reactive protein.(17) The cost of treating the 5…”
BackgroundPories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., deRamon, R. A., Israel, G., Dolezal, J. M., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00011 · Cited by 2,293 · cited 1×
“For example, longterm normalization of glucose metabolism has been reported in 83% of patients with non–insulindependent diabetes mellitus and 98% of patients with impaired glucose tolerance.(112) At East Carolina University, annual mortality was 1% in patients undergoing gastric bypass surgery compared with 4.”
BackgroundBlair, S. N. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540030039029 · Cited by 1,819
Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., & Baron, A. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118709 · Cited by 1,687
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 2×
“A serotonergic mechanism for anorectic valvulopathy was strongly suggested as early as the initial report by Connolly et al.69 Specifically, endocardial fibroplasia seen inheart valves removed from anorectic-exposed patients was described as indistinguishable from the pathologic changes unique to carcinoid syndrome (s…”
ResultSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 2×
“Long-term data for weight loss with orlistat in nondiabetic subjects is from 2 multicenter, randomized, double-blind, placebo-controlled, 2-year trials.(52,53) The first (European) study of these compared weight loss in 340 placebo-treated patients with 343 patients receiving orlistat, 120 mg 3 times daily.”
BackgroundHollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Cited by
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,495
Childhood obesity: public-health crisis, common sense cure
Ebbeling, C. B., Pawlak, D. B., & Ludwig, D. S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09678-2 · Cited by 2,980
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.007 · Cited by 2,257
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.021 · Cited by 1,702
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
2006 WRITING COMMITTEE MEMBERS, Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.190748 · Cited by 1,114
Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 593
Cellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
Weight management using a meal replacement strategy: meta and pooling analysis from six studies.
Heymsfield, S. B., van Mierlo, C. A. J., van der Knaap, H. C. M., Heo, M., & Frier, H. I. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802258 · Cited by 557
Modern science versus the stigma of obesity
Friedman, J. M. (2004) · Nature Medicine · doi:10.1038/nm0604-563 · Cited by 368
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 347
Rising Burden of Obesity in Asia
Ramachandran, A., & Snehalatha, C. (2010) · Journal of Obesity · doi:10.1155/2010/868573 · Cited by 301
The link between stress and feeding behaviour
Maniam, J., & Morris, M. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.017 · Cited by 255
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.030 · Cited by 198
Cercato, C., Roizenblatt, V. A., Leança, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., & Halpern, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.124 · Cited by 100
Central Nervous System Biogenic Amine Targets for Control of Appetite and Energy Expenditure
Nelson, D. L., & Gehlert, D. R. (2006) · Endocrine · doi:10.1385/endo:29:1:49 · Cited by 78
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Ciciurkaite, G., Moloney, M. E., & Brown, R. L. (2019) · Public Health Reports · doi:10.1177/0033354918813102 · Cited by 40
Li, Z., Hong, K., Yip, I., Huerta, S., Bowerman, S., Walker, J., Wang, H., Elashoff, R., Go, V. L. W., & Heber, D. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00126-7 · Cited by 18
Three- and six-month efficacy and safety of phentermine in a Mexican obese population
Márquez-Cruz, M., Kammar-García, A., Huerta-Cruz, J. C., Carrasco-Portugal, M. D. C., Barranco-Garduño, L. M., Rodríguez-Silverio, J., González, H. I. R., & Reyes-García, J. G. (2021) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203943 · Cited by 13
Metadata
- Authors
- Glazer, G.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2001-08-13
- Volume
- 161
- Issue
- 15
- Pages
- 1814
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2133090145
- Cited by
- 170
- References
- 14
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.